<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721747</url>
  </required_header>
  <id_info>
    <org_study_id>GOG/2007-01</org_study_id>
    <secondary_id>2007-005173-56</secondary_id>
    <nct_id>NCT00721747</nct_id>
  </id_info>
  <brief_title>Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer</brief_title>
  <official_title>Phase II, Open, Not Randomized Clinical Trial, to Evaluate the Sequential Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in her2 Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Oncológico Gallego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pivotal S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Oncológico Gallego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how many pathological complete responses are
      achieved in patients treated with taxotere® (T) followed by Myocet® (M)and Cyclophosphamide
      (MC) first line treatment in HER2 negative brest cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II, open, not randomized clinical trial, to evaluate the sequential Taxotere®, followed
      by Myocet® and Cyclophosphamide first line treatment in her2 negative breast cancer patients.

      The purpose of this study is to determine how many pathological complete responses are
      achieved in patients treated with taxotere® (T) followed by Myocet® (M)and Cyclophosphamide
      (MC) first line treatment in HER2 negative brest cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine proportion of Pathological complete responses</measure>
    <time_frame>At the end of the treatment, after Surgery.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine proportion of clinical responses</measure>
    <time_frame>At the end of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe treatment safety</measure>
    <time_frame>At the end of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine proportion of conservative breast surgery</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate disease free survival</measure>
    <time_frame>At the end of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Overall survival</measure>
    <time_frame>At the end of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate gene patterns regarding prediction of treatment response</measure>
    <time_frame>At the end of the treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Unique arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Liposomal doxorubicine and Cyclophosphamide</intervention_name>
    <description>4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv</description>
    <arm_group_label>Unique arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Brest adenocarcinoma stages II/III

          -  Female

          -  Informed consent signed

          -  HER2 negative

          -  Age&gt;18 years old

          -  ECOG &lt; 1

          -  Proper organic function regarding the following criteria:

               1. ANC &gt; 2,0 x 109L, platelets &gt; 100 x 109L and hemoglobin &gt; 10g/dL (transfusion is
                  allowed)

               2. Hepatic Function:

             i.Bilirubin &lt; 1,5 x UNL ii.AST ,ALT &lt; 2,5 x UNL iii.Alkaline phosphatase &lt; 5 UNL
             iv.Patients with AST and /or ALT &gt; 1.5 x UNL and alkaline phosphatase &gt; 2.5 x UNL will
             not be selected for the study c.Renal function: creatinine &lt; 1,25 x UNL, or creatinine
             clearance &gt; 60 mL/min d.Normal Cardiac function, confirmed with FEVI &gt;50% and
             electrocardiogram.

          -  Patients should be available for treatment and follow up and must be treated in
             investigator or co-investigator site

          -  Negative pregnancy test(performed 7 days before treatment)

        Exclusion Criteria:

          -  Previous treatment for breast cancer (CT, RT, IT, HT)

          -  Stages IIIb, IIIc or IV or invasive bilateral breast cancer

          -  Previous neoplasias treated with Anthracyclines or Taxanes (Paclitaxel or Docetaxel)

          -  Pregnant or breastfeeding females

          -  Neurotoxicity Grade 2

          -  FEV≤50% or any cardiac disease in which anthracyclines are contraindicated

          -  Other severe diseases regarding investigator criteria

          -  Any neurological or psychiatric pathology

          -  Previous neoplasia different from breast cancer except:

               1. skin cancer(no melanoma)

               2. In situ cervix Carcinoma

               3. Ipsilateral in situ ductal carcinoma

               4. In situ lobular in situ carcinoma

               5. Any other carcinoma without evidence disease in last 10 years

          -  Treatment chronic with corticoids (except patients starting 6 months before inclusion
             with low dosages (* 20 mg methylprednisolone or equivalent)

          -  Concomitant treatment with Hormone ovarian replacement therapy

          -  Contraindication for corticoids

          -  Concomitant treatment with another investigational drugs

          -  Included in another clinical trial with any drug in 30 days before inclusion study

          -  Concomitant treatment with another anticancer therapy

          -  Male patients

          -  Hypersensibility to any study drug or components
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús García Mata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo Oncológico Gallego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08906</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo</name>
      <address>
        <city>La Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>La Coruña</city>
        <state>Galicia</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Cies</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2008</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer patients her2 negative pathological responses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

